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ABSTRACT
Background and aims
Little information is available on real-life occurrence of oral thrush in COPD patients treated with ICS. We investigated oral thrush incidence in COPD patients prescribed FDC ICS/LABA therapies and assessed whether it is modulated by the ICS type, dose, and delivery device.
Methods
We conducted a historical, observational, matched cohort study (one baseline year before and one outcome year after initiation of therapy) using data from the UK Optimum Patient Care Research Database. We assessed oral thrush incidence in patients initiating long- 
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Conclusions
ICS use increases oral thrush incidence in COPD and this effect is dose-dependent for FP/SAL therapies. Of the therapies assessed, FP/SAL pMDI and BUD/FOR DPI may be more protective against oral thrush.
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INTRODUCTION
Oral thrush, also known as oral candidiasis, is a well-documented local side-effect associated with regular inhaled corticosteroid (ICS) use in patients with asthma [1] [2] [3] [4] . It is thought to be caused by a reduced local immune response 5 or an increase in salivary glucose (which stimulates growth of Candida albicans 6 ) after deposition of ICS in the oropharyngeal cavity. Many factors have been reported to influence the incidence of oral thrush in asthma, including type and dose of ICS used, mode of drug delivery, and patient compliance with medication instructions [7] [8] [9] [10] [11] . Although generally associated with temporary symptoms, ICS local side-effects, including oral thrush, can be clinically significant, and may affect patient quality of life and therapy adherence 3, 12, 13 .
ICS are also prescribed for the treatment of chronic obstructive pulmonary disease (COPD) in patients with severe airflow limitation and/or at high risk of exacerbations, and are generally recommended in combination with long-acting β 2 -agonists (LABAs) 14, 15 .
However, recent studies have found that ICS are being prescribed in COPD even more widely and frequently than would be expected from current management guidelines, particularly among less severe patients 16, 17 . Despite the widespread use of ICS in this disease, there is little information on real-life occurrence and distribution of oral thrush in patients with COPD who are prescribed ICS [18] [19] [20] [21] . The objective of this study was to investigate the incidence of oral thrush in COPD patients receiving ICS as part of their ICS/LABA combination therapy. In particular, we sought to assess whether oral thrush incidence is modulated by the type of ICS, the ICS dose, and the delivery device (dry
powder inhaler [DPI] vs pressurised metered-dose inhaler [pMDI]).
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METHODS
Study design and data source
This was a historical, observational, matched cohort study utilising healthcare records from the Optimum Patient Care Research Database (OPCRD) 22 . The OPCRD is a bespoke database with focus on patient-reported outcomes that, at the time of this study, contained anonymous data for over 2.4 million patients from over 550 UK primary care practices across England, Scotland, Wales, and Northern Ireland. It contains two types of data: (1) routinely recorded clinical data and (2) questionnaire responses from over 40,000 patients with respiratory conditions. We examined data during a one-year baseline period (prior to the index date, defined below) for patient characterisation, and a one-year outcome period after initiation of a new or additional COPD therapy. The index date was defined as the date of first prescription for either a fixed dose combination (FDC) ICS/LABA (therapies assessed described below) or long-acting bronchodilator therapy (LABA, long-acting muscarinic antagonist [LAMA], or their combination; addition of an alternative longacting bronchodilator was also considered as first prescription). This study design was necessary to determine the incidence of oral thrush, compared with a reference group without ICS exposure, and allow for seasonal changes in respiratory disease symptoms and related conditions. The study was conducted to standards suggested for observational studies, including an independent advisory group, use of an a priori analysis plan, study registration with commitment to publish, and a well-maintained and monitored study database 23 .
Ethical approval
The study was conducted and is reported in compliance with the criteria of the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP; 
Inclusion and exclusion criteria
Patients eligible for inclusion in the study received a quality outcomes framework (QOF) code for COPD diagnosis 24 , were aged ≥40 years at the index date, had at least 2 years of continuous practice data (1 year of baseline and 1 year of outcome data), and received ≥2 prescriptions of FDC ICS/LABA or long-acting bronchodilator during the outcome period (including prescriptions at the index date). Patients were excluded if in the baseline period they received ≥1 prescription for ICS, ≥1 prescription for both LABA and LAMA, maintenance oral corticosteroid prescription, or if they had a diagnostic code for any chronic respiratory disease other than COPD, asthma, or bronchiectasis.
Cohorts and treatment arms
We initially studied two cohorts of patients with COPD. Figure S1A , B). Finally, in the FP/SAL pMDI treatment arm, we conducted a subgroup analysis of patients who were prescribed a spacer in the period comprising the baseline year, the index date, and two weeks after the index date (ensuring that spacer device use preceded the occurrence of oral thrush), and compared them with patients who were not prescribed a spacer in the same period.
Exact matching
We used matching with statistical adjustment for residual confounders (exact matching, as described in previous studies 25, 26 ) in order to ensure that we analysed comparable groups of patients. We compiled a list of potential matching criteria informed by expert clinical advice and previous research experience, including variables predictive of outcomes and the key baseline clinical characteristics differing between unmatched cohorts (identified using t-test, and Chi-Squared and Mann-Whitney U tests, as appropriate). The matching criteria (described in Table S1 and Figure S1A , B) were then applied sequentially to
produce two matched cohorts containing all possible pairings; bespoke software was used to randomly select final unique matched pairs.
ICS daily doses
To better capture the relationship between ICS dose and oral thrush, we used the intended daily dose of ICS, defined as the dose prescribed at the index date. Doses are expressed in FP equivalent units (FP: BUD, 1:2 dose ratio; see Table 10 
Outcomes
The primary outcome was the incidence of oral thrush, defined as the proportion of patients with a diagnosis of oral thrush and/or prescribed antifungal medication for the treatment of oral thrush within the outcome period (occurring at distinct dates). Because oral thrush is generally successfully treated with antifungal medications (http://www.nhs.uk/conditions/Oral-thrush---adults/Pages/Introduction.aspx), different episodes can be regarded as independent cases/diagnosis.
Statistical analysis
All analyses were carried out using SAS version 9. For matched data, we used conditional logistic regression to compare oral thrush incidence between cohorts and treatment arms. For unmatched data, we used logistic regression.
Outcomes were adjusted for any residual non-collinear baseline confounders and for those 
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RESULTS
In the unmatched cohorts, we analysed observations from 13,647 patients who were prescribed FDC ICS/LABA and 10,043 observations from 9,161 patients who were prescribed non-ICS therapy ( Figure 1A , B). Matching procedure (Table S1 ) resulted in a final population of 8,255 uniquely matched patients per cohort. We characterised unmatched and matched patients according to baseline demographic and clinical features.
Overall characteristics of the unmatched populations were retained in the matched cohorts (Table 1 ). In the matched cohorts, the mean age was 69 years (SD 10), 57% of patients were male, the majority were ex-smokers (50%) or current-smokers (40%), and the mean BMI was 27 (SD 6), indicating that the majority of patients were overweight or obese.
Diabetes (18%), eczema (14-15%), and asthma (7-10%) were the most frequent comorbidities. Finally, Table 1 shows that oral thrush prevalence was low in the baseline period both in the matched (1%) and in the unmatched cohorts (3%).
Incidence of oral thrush in patients prescribed ICS
In the outcome period, the incidence of oral thrush was higher in patients prescribed FDC ICS/LABA compared with those prescribed non-ICS therapy ( 
Incidence of oral thrush by ICS drug and inhaler device
To carry out subset analyses we used matching ( Figure S1A However, the majority of patients who were on BUD/FOR DPI therapy were prescribed the medication at low ICS dose, whereas most patients on FP/SAL DPI therapy were prescribed the medication at higher ICS doses (Table S2 ). After adjusting for intended ICS daily dose, we found no significant difference in the incidence of oral thrush between the treatment arms ( A subgroup analysis revealed that oral thrush incidence was lower among patients prescribed FP/SAL pMDI with a spacer device compared with those prescribed FP/SAL pMDI without a spacer (Table S3; 
Incidence of oral thrush by ICS dose
In the cohort comprising FP/SAL pMDI and FP/SAL DPI a significantly higher number of patients prescribed high daily dose of ICS (≥1000 µg/day FP equivalent units) developed oral thrush compared with those prescribed low daily dose of ICS (<500 µg/day) ( Table S2 ).
DISCUSSION
There is limited research on the real-life incidence of oral thrush in patients with COPD who are prescribed ICS. Here, we showed that ICS therapy increases the risk of developing oral thrush in real-life patients with COPD and this effect is modulated by the delivery device and, for some ICS therapies, by dose.
We observed a significant reduction in the risk of oral thrush among patients prescribed BUD/FOR DPI compared with those prescribed FP/SAL DPI, which was likely attributable to the ICS dose prescribing patterns: in UK, the daily dose of FP/SAL DPI that is recommended for use in COPD is more than double the FP-equivalent dose of BUD/FOR DPI 29 . After adjusting for this a priori confounder, we observed no significant difference in the incidence of oral thrush between the two therapies, suggesting that if the drugs were prescribed at the same dose the risk of developing oral thrush would be M A N U S C R I P T
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14 similar. However, BUD/FOR DPI may represent a better therapeutic option to reduce the risk of oral thrush given that it is generally prescribed at lower doses (and thus associated with less amount of ICS being deposited in the oropharynx). We considered whether the difference in the prescribing patterns could be confounded by the selection of ICS therapy by general practitioners, with milder patients being prescribed BUD/FOR DPI and more severe patients being prescribed FP/SAL DPI. However, patients were matched on COPD exacerbations in the baseline period and other variables related to disease severity (COPD therapy, FEV 1 % predicted, acute oral corticosteroid courses, and lower respiratory consultations in the baseline period) were balanced between the treatment arms. Therefore, it is unlikely that disease severity was systematically different between the groups.
Several studies reported that the incidence of oral thrush is positively associated with the ICS dose among patients with asthma 7, 8, 10, 11 . Overall, we observed that a higher number of patients developed oral thrush when prescribed high daily dose of ICS compared with those prescribed low daily dose of ICS. However, this difference was only significant in the cohort comprising FP/SAL DPI and FP/SAL pMDI and, according to our exploratory analyses, it was likely driven by FP/SAL pMDI (for which the odds of developing oral thrush was 85% higher when the drug was prescribed at a high dose). The lack of dose effect in the BUD/FOR DPI arm was likely due to the fact that, as mentioned above, most patients (over 98%) were prescribed this therapy at low daily dose.
In our study, we found that delivery of FP/SAL via a pMDI device was protective against However, oropharyngeal deposition is influenced but many factors, including inhalation speed, inhaler technique, particle size, and pharyngeal and lower airway anatomy, among others 36 , which makes it challenging to truly assess differences in drug deposition between different drugs and inhalers. Thus, this hypothesis should be investigated further.
Both drug deposition in the upper airways 37,38 and oral candidiasis 39 are reduced when using a pMDI with a spacer device, likely because the portion of the dose that usually impacts in the oropharynx is left in the spacer 40 . Accordingly, we found that fewer patients developed oral thrush when using FP/SAL pMDI with a spacer than without a spacer. This result was not statistically significant, however studying this association in a larger population could result in a statistically significant outcome. As poor inhaler and spacer technique is an issue in COPD 41,42 , it is possible that the occurrence of oral thrush could be further reduced by improving knowledge of proper use of spacers.
In our study, approximately 40% of patients in each cohort were current smokers, in line with typical estimates of smoking prevalence in COPD 43 . Smoking is a known risk factor for developing oral thrush 44 . Thus, smoking may contribute to increased risk of oral thrush in patients with COPD who are smokers and are treated with ICS. However, because smoking status was a matching criterion in our study, it is unlikely that smoking habits introduced bias in our results.
We found high rates of diabetes and eczema comorbidities among patients with COPD in this study (in the study cohorts and arms, diabetes was present in approximately 20% of M A N U S C R I P T
16 patients and eczema in approximately 15% of patients). We observed that incidence of oral thrush was significantly higher in patients with COPD and diabetes prescribed ICS compared with patients with COPD and diabetes prescribed non-ICS therapy (5.9% vs 3.2%; p = 0.001). Because eczema can be caused by Candida albicans and diabetes is known to increase the risk of oral infections (owing to increased concentrations of glucose in saliva 6, 11 ), oral thrush may be a substantial issue for individuals with COPD and coexisting diabetes and/or eczema who are prescribed ICS. In these patients, a more careful consideration of which ICS should be prescribed, and at which dosage, may be appropriate. This aspect warrants further research.
Study strengths and limitations
This is one of a few studies exploring real-life incidence and determinants of oral thrush in COPD. A strength of this study is the cohort design; exposure to specific COPD therapies preceded the outcome measure, which allowed a stronger assessment of the causal association between ICS therapy, dose, and device type, and oral thrush. Our findings are also strengthened by the large sample sizes and by the use of data from primary care practices, particularly since the population investigated here is more representative of reallife patients and of the clinical setting faced by practitioners than clinical trial populations 23 . However, observational database studies may be limited by selection bias and residual confounding. Our goal in using a matching approach was to minimise cohort baseline differences and identify treatment cohorts of similar baseline COPD severity and other relevant determinants, as would occur with the randomisation process in a clinical trial.
However, we cannot entirely exclude the possibility of systematic differences between patient cohorts due to some unobserved baseline characteristics. Another study limitation is the possibility of misdiagnosis or miscoding of oral thrush in routine primary care practice.
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In the study cohorts, the incidence of oral thrush never exceeded 10%. In the literature, there is a high variability in the reported incidence of oral thrush with ICS use, with rates ranging from <1% to >70%, likely reflecting differences in diagnostic criteria, as reviewed elsewhere 3, 4 . Although a true diagnosis of oral thrush would require confirmation by culture for Candida albicans, the infection is routinely diagnosed by visual examination of the oral lesions without further confirmation, with the exception of immunocompromised or hospitalised patients. Therefore, here and in other studies, misclassification of oral thrush cannot be excluded. It is also plausible that some patients would self-diagnose oral thrush, using previous experience, and visit community-based pharmacies to treat oral infections with over-the-counter medications without visiting their general practitioner.
Thus, the incidence of oral thrush in this study may be underestimated and future research could be improved by collection of pharmacy data.
Another explanation for the relatively low rate of oral thrush in our study may be poor adherence to therapy. Although adherence is difficult to assess using primary care prescribing data, poor adherence to inhaled treatment is a well-documented issue in chronic diseases, including asthma 45 and COPD
41
. Cooper et al. (2015) 12 found that patients who are more adherent to ICS experience more side-effects (including oral thrush). OPCRD, which was used in this study, collects data on prescriptions but it does not collect data on dispensing or actual use of drugs (or spacers); therefore, we cannot determine whether all patients effectively took their medications as prescribed. On the other hand, local side-effects of ICS may be the cause of poor compliance with therapy 12, 13 . A clinical trial assessing long-term effects of ICS in COPD found that local side-effects, namely oral thrush and local irritation of the throat, were specified reasons for withdrawing from the trial 20 . This underlines the importance of investigating strategies to M A N U S C R I P T
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18 reduce oral thrush with robust study designs, as good adherence is required to achieve appropriate disease control.
CONCLUSIONS
This study indicates that ICS treatment increases the incidence of oral thrush in patients with COPD and that this effect is dose-dependent for FP/SAL therapies. Of the therapies assessed in this study, and considering real-life prescribing patterns, FP/SAL pMDI and BUD/FOR DPI may represent more protective therapies against the local ICS side-effect oral thrush. In addition, our findings support implementation of guideline recommendations on spacer use, as additional reduction in oral thrush incidence may be achieved using spacer devices, especially for COPD patients with inhaler technique coordination problems. However, both device-related and patient-related factors can influence disease outcome when using inhaler medications. Therefore, the risk of sideeffects should be carefully balanced against therapeutic outcomes, patients' preference, and patients' inhaler technique when choosing the most appropriate inhaler therapy for individual patients.
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The authors wish to thank Derek Skinner for his assistance with data extraction and analysis. Rafael Mares and Bakhtiyor Khalikulov are particularly thanked for assistance with study design and data extraction during the preliminary phase of the study. Tables   Table 1: Baseline demographic and clinical Measured as kg/m 2 # mMRC score is used to assess the severity of breathlessness; both mMRC scores recorded in routine medical practice and patient mMRC scores were used, with the most recent score taking precedence ** Moderate/severe exacerbations within the baseline period included occurrence of any of the following: (a) acute course of oral corticosteroids; (b) antibiotics prescribed with a lower respiratory consultation; (c) COPDrelated hospital admission to emergency department or hospital for COPD; (d) recorded hospitalisation admission on same day as a lower respiratory consultation (excluding the cases in which the only lower respiratory code recorded on that day was for a lung function test) † † Defined as all courses that are not maintenance therapy and/or all courses for which dosing instructions suggest exacerbation treatment (e.g. tapering doses from 6 to 1, or 30 mg as directed) and/or all courses with no dosing instructions but unlikely to be maintenance therapy owing to prescription strength or frequency of prescriptions ‡ ‡ Lower respiratory consultation refers to lower respiratory diagnostic codes (including asthma, COPD, and lower respiratory tract infection [LRTI] read codes), or asthma/COPD review codes excluding any monitoring letter codes, or lung function and/or asthma monitoring AND any additional respiratory examinations, referrals, chest x-rays, or events. When >1 oral corticosteroid courses/antibiotic prescriptions occurred within 2 weeks of each other, these events were considered to be the result of the same course § § GOLD grades based on 2011 GOLD guidelines 14 : A = Low risk, low symptom burden, mMRC = 0-1 and FEV 1 ≥ 50% and/or low exacerbation rate (0-1/year); B = Low risk, higher symptom burden, mMRC ≥ 2 and FEV 1 ≥ 50% and/or low exacerbation rate (0-1/year); C = High risk, low symptom burden, mMRC = 0-1 and M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT FEV 1 < 50% and/or high exacerbation rate (≥ 2/year); D = High risk, higher symptom burden, mMRC ≥ 2 and FEV 1 < 50% and/or high exacerbation rate (≥ 2/year) ¶ ¶ With a diagnostic code recorded at any time prior to or at the index date; asthma patients with asthma resolved codes were excluded ## Calculated for the year prior to index date Abbreviations: ICS = inhaled corticosteroids; LABA = long-acting β 2 -agonist; OR = odds ratio *Cohorts matched on the following baseline variables: sex, age (±5 years), smoking status, body mass index (BMI), COPD exacerbations (categorised), COPD therapy, nasal corticosteroids, oral thrush diagnosis and/or medication, and diabetes diagnosis and/or medication (see Table S1 ) M A N U S C R I P T M A N U S C R I P T
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*Cohorts matched on the following baseline variables: sex, age (±5 years), smoking status, COPD exacerbations (categorised), oral thrush diagnosis and/or medication, and diabetes diagnosis and/or medication (see Figure S2 ) † Matching variable ‡ Measured as kg/m 2 § mMRC score is used to assess the severity of breathlessness; both mMRC scores recorded in routine medical practice and patient mMRC scores were used, with the most recent score taking precedence ¶ Moderate/severe exacerbations within the baseline period included any of the following: (a) acute course of oral corticosteroids; (b) antibiotics prescribed with a lower respiratory consultation; (c) coded admission to emergency department or hospital for COPD; (d) recorded hospitalisation admission on same day as a lower respiratory consultation (excluding the cases in which the only lower respiratory code recorded on that day was for a lung function test) # Defined as all courses that are not maintenance therapy and/or all courses for which dosing instructions suggest exacerbation treatment (e.g. 6-1 reducing, or 30 mg as directed) and/or all courses with no dosing instructions but unlikely to be maintenance therapy owing to prescription strength or frequency of prescriptions ** Lower respiratory consultation refers to lower respiratory diagnostic codes (including asthma, COPD, and lower respiratory tract infection [LRTI] read codes), or asthma/COPD review codes excluding any monitoring letter codes, or lung function and/or asthma monitoring AND any additional respiratory examinations, referrals, chest x-rays, or events. When >1 oral corticosteroid courses/antibiotic prescriptions occurred within 2 weeks of each other, these events were considered to be the result of the same course † † GOLD grades based on 2011 GOLD guidelines 14 : A = Low risk, low symptom burden, mMRC = 0-1 and FEV 1 ≥ 50% and/or low exacerbation rate (0-1/year); B = Low risk, higher symptom burden, mMRC ≥ 2 and FEV 1 ≥ 50% and/or low exacerbation rate (0-1/year); C = High risk, low symptom burden, mMRC = 0-1 and FEV 1 < 50% and/or high exacerbation rate (≥ 2/year); D = High risk, higher symptom burden, mMRC ≥ 2 and FEV 1 < 50% and/or high exacerbation rate (≥ 2/year) § § With a diagnostic code recorded at any time prior to or at the index date; asthma patients with asthma resolved codes were excluded ¶ ¶ Calculated for the year prior to index date M A N U S C R I P T 
29
